Simply Wall St.
How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management?
📊
AI Sentiment
Positive
6/10
- Home
- ARWR
as of 12-02-2025 10:23am EST
$57.49
+$1.24
+2.20%
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Chart Type:
Time Range:
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 5.6B | IPO Year: | 1993 |
| Target Price: | $55.50 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.57 - $59.15 | Next Earning Date: | 11-25-2025 |
| Revenue: | $829,448,000 | Revenue Growth: | 23258.15% |
| Revenue Growth (this year): | -49.16% | Revenue Growth (next year): | -16.52% |
AI-Powered ARWR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 16 hours ago
AI Recommendation
hold
Model Accuracy: 78.91%
78.91%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
Ferrari Mauro
Sell
Director
ARWR Nov 28, 2025
Avg Cost/Share
$56.39
Shares
8,750
Total Value
$493,412.50
Owned After
68,764
SEC Form 4
Hamilton James C
Sell
Chief Medical Officer
ARWR Oct 1, 2025
Avg Cost/Share
$35.00
Shares
20,000
Total Value
$700,000.00
Owned After
212,122
SEC Form 4
Hamilton James C
Sell
Chief Medical Officer
ARWR Sep 12, 2025
Avg Cost/Share
$30.00
Shares
15,000
Total Value
$450,000.00
Owned After
212,122
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ferrari Mauro | ARWR | Director | Nov 28, 2025 | Sell | $56.39 | 8,750 | $493,412.50 | 68,764 | |
| Hamilton James C | ARWR | Chief Medical Officer | Oct 1, 2025 | Sell | $35.00 | 20,000 | $700,000.00 | 212,122 | |
| Hamilton James C | ARWR | Chief Medical Officer | Sep 12, 2025 | Sell | $30.00 | 15,000 | $450,000.00 | 212,122 |
Latest Arrowhead Pharmaceuticals Inc. News
ARWR Breaking Stock News: Dive into ARWR Ticker-Specific Updates for Smart Investing
Insider Monkey
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval
📈
AI Sentiment
Highly Positive
9/10
Simply Wall St.
Arrowhead Pharmaceuticals (ARWR) Is Up 48.1% After First FDA Approval for siRNA Rare Disease Therapy
📈
AI Sentiment
Highly Positive
8/10
Motley Fool
Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today
📈
AI Sentiment
Highly Positive
9/10
BioPharma Dive
Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3
📊
AI Sentiment
Positive
6/10
Compare ARWR vs Leading Stocks
See how ARWR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.